Natural Aminoacyl tRNA Synthetase Fragment Enhances Cardiac Function after Myocardial Infarction by McCormick, Margaret E. et al.
Natural Aminoacyl tRNA Synthetase Fragment Enhances
Cardiac Function after Myocardial Infarction
Margaret E. McCormick1, Mauricio Rojas2, Tyler Moser-Katz1, Ellie Tzima1,2, John S. Reader1*
1Department of Cell Biology and Physiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America, 2UNC McAllister Heart
Institute, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America
Abstract
A naturally-occurring fragment of tyrosyl-tRNA synthetase (TyrRS) has been shown in higher eukaryotes to ‘moonlight’ as a
pro-angiogenic cytokine in addition to its primary role in protein translation. Pro-angiogenic cytokines have previously been
proposed to be promising therapeutic mechanisms for the treatment of myocardial infarction. Here, we show that systemic
delivery of the natural fragment of TyRS, mini-TyrRS, improves heart function in mice after myocardial infarction. This
improvement is associated with reduced formation of scar tissue, increased angiogenesis of cardiac capillaries, recruitment
of c-kitpos cells and proliferation of myocardial fibroblasts. This work demonstrates that mini-TyrRS has beneficial effects on
cardiac repair and regeneration and offers support for the notion that elucidation of the ever expanding repertoire of
noncanonical functions of aminoacyl tRNA synthetases offers unique opportunities for development of novel therapeutics.
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Introduction
The primary functional role of the aminoacyl-tRNA synthetases
(aaRSs) is to ligate specific amino acids to their canonical tRNAs in
the first step of protein synthesis. In the last decade, there has been
the growing realization that these enzymes have a wide range of
additional cell signaling functions outside of their canonical
‘housekeeping’ roles in higher eukaryotes [1]. Non-canonical
functions of aaRSs include regulation of angiogenesis, inflamma-
tion and tumorigenesis, while genetic mutations in human aaRSs
are now thought of as causative factors for the pathology of several
diseases [2]. The first example of a ‘moonlighting’ aaRS was
human cytosolic tyrosyl-tRNA synthetase (TyrRS) [3], which is
secreted from endothelial cells (ECs) as a natural fragment – mini-
TyrRS [4]. Once outside the confines of the cell, mini-TyrRS can
activate angiogenic signaling pathways in ECs in vitro and
stimulate angiogenesis in vivo [5], as well as function as a
chemo-attractant to white blood cells [3]. The ever-expanding
roles of aaRSs and their fragments (now branded Physiocrines) in
human physiology and pathology hold the promise of their use as
therapeutic reagents and pharmacological targets.
Heart disease is a leading cause of death in developed countries;
acute occlusion of a major coronary artery leads to cardiac
ischemia due to reduction or elimination of blood flow, loss of
cardiac tissue, and its subsequent replacement with non-functional
scar tissue [6]. Although the area that experiences complete loss of
blood supply suffers irreversible damage, the myocardium
surrounding the infarct zone is thought to be capable of recovery
if angiogenesis and restoration of blood flow occur [7,8]. In this
vein, efforts have focused on the timely revascularization of the
ischemic myocardium by delivery of angiogenic and chemotactic
molecules, including vascular endothelial growth factor (VEGF),
basic fibroblast growth factor (bFGF, FGF2), stromal cell derived
factor-1 (SDF-1), hepatocyte growth factor (HGF), to name a few
[9–11]. For example, cardiac-specific over-expression of FGF2
results in enhanced recovery of cardiac contractile function and
reduced infarct size after ischemia-reperfusion injury [12], while
increased expression of nerve growth factor (NGF) promotes
angiogenesis and survival of cardiomyocytes after MI and leads to
increased levels of c-kitpos progenitor cells in hearts [13]. Similar c-
kitpos cell homing to infarcted hearts was noted in response to
stromal cell-derived factor-1a [8,14]. Additionally, several studies
have utilized stem cells, both embryonic stem cells (ESCs) and
induced pluripotent stem cells (iPSCs), as well as epicardium
derived cells, to regenerate the heart [15–22].
It is universally accepted that ECs play a crucial role in
regulating the survival and function of neighboring cardiomyo-
cytes by promoting angiogenesis and vascular regeneration, but
also by regulating cardiomyocyte contractility and growth via
paracrine signaling [23]. Signaling downstream of mini-TyrRS
can trigger EC migration, proliferation and angiogenesis [4]. On
the basis of these properties of mini-TyrRS and its previously
reported chemotactic activity, we investigated the potential for
mini-TyrRS to promote murine cardiac recovery and function in
response to coronary occlusion. We found that mice treated with
mini-TyrRS after MI do indeed have improved recovery of heart
function. These changes in hearts in response to mini-TyrRS are
associated with a decrease in cardiac fibrosis, an increase in
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angiogenesis of cardiac capillaries, proliferation of cardiac
fibroblasts and increased levels of c-kitpos progenitor cells in hearts.
Materials and Methods
Animals
Adult (12 weeks), male C57Bl/6 mice were purchased from
Jackson Laboratories (Bar Harbor, ME, USA).
Ethics statement
Animals were used in accordance with the guideline of the
National Institute of Health and for the care and use of laboratory
animals (procedures were approved by the Institutional Animal
Care and Use Committees of the University of North Carolina at
Chapel Hill).
Echocardiography
Conscious echocardiography was performed as previously
described using a Vevo 2100 ultrasound biomicroscopy system
[24]. All LV dimension data are presented as the average of at
least 3 independent waveforms.
Left anterior descending coronary artery ligation (LAD)
and mini-TyrRS treatment
Mouse surgeries were performed as previously described [25].
Briefly, mice were anesthetized with isoflurane and a thoracotomy
was performed for ventilation. The chest was then opened, the
peri-cardial sac opened and the LAD artery was permanently
occluded with a suture. For sham injury, an identical procedure
was followed. Body temperature was monitored with a rectal
probe. Endotoxin-free, recombinant mini-TyrRS (250 ng/g),
prepared as previously described [26], or bacteriostatic saline
was injected IP daily on days 0–6 after surgery.
Histological analysis and Immunofluorescence
Hearts were perfused and fixed with fresh 4% paraformalde-
hyde for 24 hours. The hearts were then paraffin embedded and
sectioned into 5 mm sections and stained with hematoxylin and
eosin or Masson’s trichrome to assess overall morphology [27]. For
determination of scar area, ImageJ software was used to trace the
fibrotic area (blue) from an image taken through the middle of the
LV and expressed as fibrotic area relative to total area. For
determination of capillary density, heart sections were stained with
TRITC-conjugated lectin (Triticum vulgaris) and examined by
fluorescence microscopy as previously described [24,27]. Specif-
ically, for each heart section (10 images/mouse), the number of
lectin-positive vessels surrounding round cardiomyocytes was
counted. These values were then averaged to yield the average
vessel density per cardiomyocyte. For immunohistochemistry,
antibodies used were: CD45 (rat), BD Pharmingen; CC3 (rabbit),
Cell Signaling; PCNA, Abcam; c-kit (H300) (rabbit); vimentin
(goat), Santa Cruz.
Quantitation and statistical analysis
Probability values were obtained by performing a 2-tailed
Student t-test; statistical significance was defined as P,0.05.
Results
Systemic mini-TyrRS delivery improves cardiac function
after infarction
To test the hypothesis that mini-TyrRS could improve heart
function after MI, we performed left anterior descending (LAD)
coronary artery ligations in adult (12–14 weeks) male mice.
Ligation of the LAD results in blockade of blood flow to a portion
of the left ventricle (LV), thus creating a zone of ischemia.
Following surgery, mice were given intraperitoneal (IP) injections
of either sterile saline control or 250 ng/g mini-TyrRS for 3 days.
Mice were subjected to conscious echocardiography to assess
cardiac function either pre-LAD or 3 days (3d) and 7d after LAD
(Table I). Although both treatment groups had a significant
decrease in heart function in response to MI, mini-TyrRS-treated
mice had attenuated LV dysfunction compared to the saline-
treated group, as indicated by both fractional shortening (FS) and
ejection fraction (EF) (Figure 1B, C; Table I). At 3d after
infarction, LVs of saline treated mice had a mean FS of
13.461.92% (n= 8); whereas mini-TyrRS treatment resulted in
a mean FS of 21.662.8% (n= 9). As a second measure of cardiac
function, echocardiographic measurements revealed that the mean
fraction of blood ejected from the LV in saline-treated mice was
28.863.9%, compared with a mean of 43.865% for the mini-
TyrRS-treated group. At 7d after infarction we similarly observed
an increase in cardiac function of mini-TyrRS-treated mice. FS
was 14.062.08 (n= 9) for the saline-treated group and 24.261.99
(n= 7) for the mini-TyrRS-treated group (p = 0.077), and EF was
29.564.14 (n= 9) for the saline-treated group and 46.763.35
(n= 7) for the mini-TyrRS-treated group (p = 0.086) (Figure 1).
Consistent with these results, end diastolic and end systolic
volumes at 7d were lower in the mini-TyrRS-treated group
compared to the saline-treated group (126.9 vs 62.1 ml and 94.2 vs
40.8 ml, respectively), although these values did not reach
statistical significance due to the high variability amongst animals
(p = 0.076 and p= 0.089, respectively) (Figure 1D). Importantly,
we found that mini-TyrRS administration in the absence of
infarction did not lead to an increase in cardiac function (Table I).
Collectively, these results indicate that mini-TyrRS treatment
leads to a significant improvement of murine heart function after
myocardial infarction.
Mini-TyrRS treated hearts have reduced levels of scar
formation after infarction
Myocardial infarction leads to hypoxic conditions in the heart
and subsequent death of cardiomyocytes; to maintain the
structural integrity of the heart after this significant tissue loss,
cardiac fibroblasts migrate into the damaged infarct area and
increase deposition of extracellular matrix components, including
collagen, thus leading to a build up of non-contractile scar tissue in
these recovering hearts [28]. Histological analysis of heart
morphology and scar tissue formation by hematoxylin and eosin
and Masson’s trichrome staining revealed a marked reduction in
the size of the scar tissue area and LV wall that appeared to be
thicker after mini-TyrRS treatment (Figure 2). The fibrotic area in
mini-TyrRS-treated hearts was ,61% relative to saline-treated
controls. These results show that mini-TyrRS treatment of murine
hearts after myocardial infarction is associated with a reduction in
the levels of scar tissue formation and an accompanying thicker
functional LV wall.
Mini-TyrRS treatment after myocardial infarction results
in enhanced angiogenesis
Previous work with ECs showed that mini-TyrRS promotes
angiogenesis by activating angiogenic signaling pathways within
ECs [4,5]. As vascularization of the heart is critical for
cardiomyocyte survival, we hypothesized that mini-TyrRS induces
neoangiogenesis. To test this, we harvested hearts and stained with
TRITC-lectin to visualize capillaries within the ischemic border
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region. Quantification of the capillaries revealed a statistically
significant increase in microvasculature in mini-TyrRS-treated
hearts compared to the saline controls (Figure 3). These results
suggest that the cardioprotective effects of mini-TyrRS may, in
Figure 1. Mini-TyrRS treatment after coronary ligation improves myocardial function in vivo. A. Representative images of M-Mode
echocardiography for heart function of saline- and mini-TyrRS treated mice at 3d and 7d post MI. B–C. Left ventricle fractional shortening and ejection
fraction after coronary artery ligation with or without mini-TyrRS treatment. Echocardiography results shown are mean 6 SEM (n = 7–12 mice per
group; P,0.03). Measurements were collected at the level of the papillary muscle in M-mode. D–E. End Diastolic volume and end systolic volume
after coronary artery ligation with or without mini-TyrRS treatment. Results shown are mean 6 SEM (n= 7–12 mice per group). Although results did
not reach statistical significance (P,0.09), there is a trend towards significance for decreased end diastolic and end systolic volumes after mini-TyrRS
treatment compared to saline controls.
doi:10.1371/journal.pone.0109325.g001
Table 1. Echocardiographic data from saline- and mini-TyrRS-treated hearts pre and post-LAD.
Saline Mini-TyrRS
Pre-LAD (n=11) 3d (n=8) 7d (n=9) Pre-LAD (n=11) 3d (n =9) 7d (n=7)
HR (BPM) 653.4621.8 644623.6 685615.5 688611.3 674.5615.1 657.766.29
IVS; d (mm) 1.0160.03 0.7460.06 0.7260.08 1.0060.01 0.8560.09 0.6760.03
IVS; s (mm) 1.5660.04 0.9060.11 0.9960.12 1.5860.03 1.1460.09 0.9260.06
LVPW; d (mm) 0.9660.03 0.7760.0 0.7160.09 0.9660.02 0.8860.04 0.8960.04
LVPW; s (mm) 1.3660.04 0.9360.07 0.8260.10 1.4760.05 1.1160.06* 1.1060.05*
EDV (ml) 23.561.5 78.8613.1 126.0626.7 26.561.7 64.869.0 62.166.89
ESV (ml) 5.460.7 57.6611.4 94.2622.4 5.560.7 39.968.4 40.866.4
EF% 77.362.1 28.863.9 29.564.1 79.661.7 43.865.0* 46.763.4*
FS% 44.561.9 13.461.9 14.062.1 46.861.7 21.662.8* 24.262.0*
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part, be attributed to increased cardiac neovascularization, and
therefore perfusion, of the tissue surrounding the infarct.
Mini-TyrRS reduces myocardial apoptosis after infarction
To investigate further the mechanism by which mini-TyrRS
improves cardiac function, we examined the degree of apoptosis in
the infarct zone and the neighboring ischemic zone by immuno-
staining with anti-cleaved caspase 3 antibody (CC3). Quantitation
revealed a significant reduction in the number of CC3-positive
cells in the ischemic zone of mini-TyrRS-treated hearts, compared
to saline-treated hearts (Figure 4). There was no detectable CC3
staining in areas remote from the ischemia for either treatment
group (data not shown). Thus, mini-TyrRS protects the neigh-
boring ischemic zone from apoptosis in response to infarction.
Mini-TyrRS treatment promotes cardiac fibroblast
proliferation after infarction
In response to cardiomyocyte necrosis in the infracted heart, cell
migration and proliferation is associated with the healing phase of
cardiac remodeling [29]. During this time, cardiac fibroblasts
display high proliferative activity and migration through the
matrix network [29]. We assayed cell proliferation at the border
zone by nuclear proliferating cell nuclear antigen (PCNA) staining.
Proliferation in the peri-infarct area was increased in mini-TyrRS-
Figure 2. Mini-TyrRS reduces levels of scar formation after infarction. A. Representative H&E and Masson’s Trichrome stained sections 3d
after coronary artery ligation and saline or mini-TyrRS treatment. B. Quantitation of scar tissue of hearts after coronary artery ligation; results are
represented as fibrotic area/left ventricle area, mean 6 SEM (n= 3 mice/group; 1 section taken from the middle of the LV was quantified/mouse, P,
0.03). Bar is 50 um.
doi:10.1371/journal.pone.0109325.g002
Figure 3. Mini-TyrRS treatment enhances vascularization after infarction. A. Representative TRITC-lectin stained sections 3d after coronary
artery ligation and saline or mini-TyrRS treatment. B. Quantitation of capillaries per cardiomyocyte; values shown are mean 6 SEM (n= 3 mice/group;
9–11 images were quantified/mouse; *P,0.04). Bar is 20 um.
doi:10.1371/journal.pone.0109325.g003
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treated hearts compared to saline-treated hearts (Figure 5). As
significant fibroblast proliferation has been documented in the
infracted heart, we immunostained sections with an anti-vimentin
antibody and quantitated the number of PCNA- and vimentin-
positive cells; as seen in Figure 5, mini-TyrRS treatment resulted
in significant increase in proliferating fibroblasts, compared to
saline treatment.
Effects of mini-TyrRS treatment on c-kitpos cells in the
heart after infarction
The discovery of proliferating myocytes in the human heart
after infarction has led to the identification of resident cardiac
progenitor cells [30]; multiple cell types have been identified as
progenitors based on the expression of stem cell markers, including
the tyrosine kinase receptor, c-kit [31,32]. Because of the known
chemoattractant cytokine activity of mini-TyrRS [3–5,33], we
tested the intriguing hypothesis that mini-TyrRS may act as a
‘homing’ signal to promote the recruitment of c-kitpos cells to the
infarcted heart. We examined the presence of c-kitpos, cells by
immunostaining heart tissues with a c-kit antibody (Figure 6). Our
results show that mini-TyrRS increases the abundance of c-kitpos
cells in the area surrounding the infarct, suggesting that mini-
TyrRS may promote the recruitment of these cells to the infarcted
heart to aid in recovery after ischemia. We also examined possible
differences in leukocyte migration in mini-TyrRS- and saline-
treated hearts after infarction by immunostaining for CD45, a
pan-leukocyte marker (Figure S1). We found no significant
differences in leukocyte accumulation in the infarct or peri-infarct
areas of the heart after MI in the two treatment groups.
Discussion
In this study, we present evidence that systemic delivery of the
biologic mini-TyrRS has angiogenic and cell-protective effects that
ultimately result in improved cardiac recovery in a murine
myocardial infarction model. After acute myocardial infarction in
mice, mini-TyrRS resulted in increased angiogenesis, decreased
cell apoptosis, increased proliferation and recruitment of c-kitpos
cells, providing potential mechanisms for the improved cardiac
function observed.
Previous reports have demonstrated the chemotactic effects of
mini-TyrRS on polymorphonuclear leukocytes [33], as well as its
pro-angiogenic effects on ECs [4,5]. The angiogenic effects of
mini-TyrRS have also been demonstrated in vivo [5,34,35] using
the chicken chorioallantoic membrane (CAM) assay; mouse
matrigel assay; and two models of ischemia. Our own laboratory
has provided a mechanistic basis for the action of mini-TyrRS in
angiogenesis: we have shown that mini-TyrRS activates three key
regulatory signaling pathways in ECs: ERK, Akt and Src, and
stimulates EC proliferation and migration [4]. Mini-TyrRS was
also found to induce activation of eNOS and a transient increase
in EC permeability [4]. Collectively, these studies demonstrated
the proangiogenic properties of mini-TyrRS and allowed us to
hypothesize that mini-TyrRS is beneficial in the clinically-relevant
setting of myocardial infarction.
The cardiac improvement in response to mini-TyrRS treatment
suggests that preservation of myocardial tissue and the concurrent
increase in microvascular density may be involved in the observed
cardiac recovery. The rapid improvement of cardiac function after
mini-TyrRS treatment raises the possibility that mini-TyrRS
preserves myocyte viability via cell-autonomous effects. Mini-
TyrRS is a survival signal for ECs, but a similar activity on
cardiomyocytes has not been demonstrated. Alternatively, it is also
possible that mini-TyrRS treatment rescues cardiomyocytes at the
Figure 4. Mini-TyrRS promotes cell survival after coronary artery ligation. A. Representative cleaved caspase-3 (CC3) stained sections 7d
after coronary artery ligation and saline or mini-TyrRS treatment. B. Quantitation of CC3 positive cells/image; values shown are mean 6 SEM (n = 3
mice/group; 10 images were quantified/mouse; *P,0.05). Bar is 100 um.
doi:10.1371/journal.pone.0109325.g004
Mini-TyrRS Enhances Cardiac Function after Infarction
PLOS ONE | www.plosone.org 5 October 2014 | Volume 9 | Issue 10 | e109325
Figure 5. Mini-TyrRS treatment promotes cardiac fibroblast proliferation after infarction. A. Representative sections of hearts 3d after
coronary artery ligation and saline or mini-TyrRS treatment. Sections were immunostained for vimentin, PCNA and DAPI. B. Quantitation of vimentin-
and PCNA- double positive cells in saline and mini-TyrRS treated hears; values represent fold change relative to saline group; values shown are mean
6 SEM (n= 3 mice/group; 10 images were quantified/mouse; *P,0.05). Please note the increased number of vimentin-positive cells infiltrating hearts
of mini-TyrRS-treated animals. Bar is 100 um.
doi:10.1371/journal.pone.0109325.g005
Figure 6. Increased c-Kitpos cells in mini-TyrRS-treated hearts after infarction. A. Representative c-kit stained sections 3d after coronary
artery ligation and saline or mini-TyrRS treatment. Arrows point to typical c-kit positive cells. B. Quantitation of c-kit positive cells/image; values
shown are mean 6 SEM (n = 3 mice/group; 15–16 images were quantified/mouse; *P,0.01). Bar is 100 um.
doi:10.1371/journal.pone.0109325.g006
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ischemic border zone via vasodilation of residual vessels; indeed,
we have previously shown that mini-TyrRS induces activation of
the vasodilatory enzyme eNOS in ECs [4]. Enhanced NO
bioavailability has also been linked to attenuation of vessel loss
and stimulation of angiogenesis during myocardial infarction [36].
The presence of stem cells in the heart after infarction is now
well-documented and has received much attention [31]. In
particular, c-kitpos cells have been identified in the adult
mammalian heart after infarction [30,32] and have also been
shown to have therapeutic effects when injected into mouse, rat
and porcine infarct models [31,37,38]. Although the mechanisms
underlying the therapeutic effects of cardiac stem cells are still
under investigation, as well as contention, it has been shown that
following injection of cardiac stem cells, large numbers of newly
formed, albeit immature, cardiomyocytes are seen [39]. Addition-
ally, substantial numbers of arterioles and capillaries are also seen,
suggesting that cardiac stem cells can also differentiate into ECs
[31]. Although we do not know at this point the fate of the c-kitpos
cells recruited in response to mini-TyrRS treatment, we hypoth-
esize that the presence of these cells in the remodeling hearts
contributes to cardiac regeneration and recovery. It is also possible
that mini-TyrRS stimulates recruitment and proliferation of
cardiac fibroblasts that secrete factors that promote angiogenesis
and cardiomyocyte survival. Therefore, cardiac improvement
associated with mini-TyrRS treatment may be multi-factorial,
involving effects on various resident cardiac cells and effects on
tissue survival, angiogenesis and stem cell recruitment.
The effects of mini-TyrRS on stimulating fibroblast prolifera-
tion, yet reducing scar tissue compared to saline-treated hearts
might on first look seem contradictory. One of the well-known
functions of cardiac fibroblasts is the synthesis and breakdown of
extracellular matrix components [28]; this process is particularly
important during the cardiac remodeling that follows an
infarction. Degradation of collagen and other extracellular matrix
constituents requires activation of MMPs; interestingly, we have
previously shown that mini-TyrRS activates MMP2 in vascular
ECs [4]. In the early stages following cardiac injury, infiltrating
inflammatory cells secrete cytokines and growth factors that
promote fibroblast activation, proliferation and differentiation,
followed by deposition of new matrix proteins and scar formation.
At this stage, increases in matrix proteins and scar tissue is
considered reparative, as it serves to replace areas of cardiomy-
ocyte loss; however, if this process persists uncontrollably, it may
become maladaptive and ultimately lead to reduced cardiac
function [40]. Our data suggest that while mini-TyrRS promotes
cardiac fibroblast proliferation and recruitment to the site of
injury, this process is tightly regulated so that it results in reduced
scar tissue and increased cardiac function. In fact, the cardiac
fibroblast is not just a bystander that functions merely to increase
fibrosis; it has recently been shown that cardiac fibroblasts are
crucial players in cardiac adaptive responses [41], possibly via
secretion of paracrine factors [42] that result in cardiomyocyte
hypertrophy and overall cardiac protective effects [43,44].
Our research explores the potential for the naturally occurring
biologic mini-TyrRS to act as a therapeutic for the treatment of
myocardial infarction. There are several properties of mini-TyrRS
that make it an attractive candidate for therapeutic development.
First, we administered mini-TyrRS by IP injection rather than
intracardially at the site of injury. Secondly, in contrast to the early
administration of most other cytokines or growth factors before
coronary artery ligation, mini-TyrRS was administered a few
hours after infarction, therefore more closely resembling a
clinically-relevant setting. Finally, development of therapeutics
based on naturally-occurring secretory biologics, such as mini-
TyrRS, might provide a new strategy for developing novel
therapeutics with minimal unwanted side-effects.
The last decade has seen skyrocketing interest in the field of
tRNA synthetase biology, especially their expanding participation
in multiple cellular functions and their increasing appreciation as
causative agents for human diseases. Our study reveals that
delivery of mini-TyrRS after infarction clearly provides therapeu-
tic in vivo benefits and adds to the repertoire of non-canonical
aaRS functions.
Supporting Information
Figure S1 Effects of mini-TyrRS treatment on CD45-positive
cells in the heart after infarction. A. Representative CD45 stained
sections after coronary artery ligation and saline or mini-TyrRS
treatment. Areas at the infarct and peri-infarct sites are shown. B.
Quantitation of CD45 positive cells/image; values shown are
mean 6 SEM (n=3/group; 10 images/mouse). Bar, 80 um.
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